- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06384807
Une étude de phase 1/2 du PBI-410 dans les tumeurs solides avancées
Une étude de phase 1/2, première chez l'homme, sur l'augmentation et l'expansion de la dose du PBI-410 chez des participants atteints de tumeurs solides avancées
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510, a Trop-2 directed antibody-drug conjugate (ADC), in participants with previously treated, advanced solid tumors. The study comprises 2 parts: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion. The Phase 1 will investigate the safety and tolerability of BHV-1510 given in monotherapy and given in combination with cemiplimab and identify one or more recommended doses for expansion (RDEs) and the maximum-tolerated dose (MTD) (if one exists). Once the RDE has been established, Phase 2 will open to investigate the preliminary efficacy of BHV-1510 in signal-finding expansion cohorts.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Chief Medical Officer
- Numéro de téléphone: 203-404-0410
- E-mail: clinicaltrials@biohavenpharma.com
Lieux d'étude
-
-
California
-
Duarte, California, États-Unis, 91010
- Recrutement
- Site-113
-
La Jolla, California, États-Unis, 92093
- Recrutement
- Site-112
-
Palo Alto, California, États-Unis, 94304
- Recrutement
- Site-111
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20016
- Recrutement
- Site-114
-
-
Florida
-
Miami, Florida, États-Unis, 33176
- Recrutement
- Site-103
-
Orlando, Florida, États-Unis, 32827
- Recrutement
- Site-105
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Site-115
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30912
- Recrutement
- Site-110
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48201
- Recrutement
- Site-109
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63108
- Complété
- Site-101
-
-
New York
-
New York, New York, États-Unis, 10021
- Recrutement
- Site-117
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73117
- Recrutement
- Site-116
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Recrutement
- Site-108
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Recrutement
- Site-107
-
-
Texas
-
Dallas, Texas, États-Unis, 75231
- Recrutement
- Site-104
-
-
Utah
-
West Valley City, Utah, États-Unis, 84119
- Recrutement
- Site-106
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Site-102
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
Male or female participants aged ≥18 years.
-
Unresectable, incurable, locally advanced or metastatic epithelial-origin solid tumor that is refractory to standard therapies, or has no approved standard therapies, or no approved standard therapies at its current treatment stage. If applicable to the tumor type, participants must have received platinum-based chemotherapy, standard of care immunotherapy, and standard of care targeted therapies.
-
Measurable disease (per RECIST 1.1).
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
-
Participants have adequate hematologic, renal, liver, and coagulation function as defined by the following (blood transfusion or growth factor support is not allowed within 7 days prior to blood samples that will be used to establish eligibility):
- Hemoglobin ≥9 g/dL
- Absolute neutrophil count >1,500/mm3; participants with known Duffy null phenotype who have absolute neutrophil count ≥1,200/mm3 may be enrolled
- Platelets >100,000/mm3
- Creatinine clearance ≥50 mL/min measured or estimated using the Cockcroft-Gault formula; 24-hour urine collection is allowed, but not required.
- Total bilirubin ≤1.5 × upper limit of normal (ULN); participants with known Gilbert's syndrome who have total bilirubin level ≤3×ULN may be enrolled.
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5×ULN (or ≤5×ULN for participants with hepatic metastases)
- Alkaline phosphatase <2.5×ULN (or ≤5×ULN for participants with hepatic and/or bone metastases)
- International normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN
- Activated partial thromboplastin time (aPTT) ≤1.5×ULN. Study participants on therapeutic doses of anticoagulation medication must have INR and/or aPTT ≤ the upper limit of the therapeutic range for intended use
-
Have recovered (ie, improvement to Grade 1 or better) from all acute toxicities from previous therapy, excluding alopecia and vitiligo.
BHV-1510 in Combination with specific inclusion criteria:
- histologically or cytologically documented advanced (locally, recurrent, inoperable, cannot betreated with curative intent) or metastatic cancer including Endometrial Carcinoma that is confirmed as proficient mismatch repair (pMMR)
- received ≤ 2 prior lines of systemic anti-cancer therapy and at most one prior anti-programmed cell death protein 1 (PD-1) (programmed death-ligand 1 [PD-L1]) therapy for advanced/ metastatic disease.
Key Exclusion Criteria:
- Women who are pregnant or lactating.
- Clinically significant intercurrent disease.
- Has symptomatic brain metastases or has had any radiation or surgery for brain metastases within 4 weeks of C1D1.
- Has clinically significant corneal disease.
- Requires supplemental oxygen for daily activities.
- Previous treatment with a Trop-2-targeted therapy, including Trop-2 ADCs.
- Has a medical history of interstitial lung disease (eg, noninfectious interstitial pneumonia requiring steroid treatment, pneumonitis, pulmonary fibrosis, or severe radiation pneumonitis) or current interstitial lung disease or are suspected to have any of these diseases based on imaging at Screening.
- Any standard cancer therapy (eg, chemotherapy, hormonal therapy, radiotherapy, immunotherapy, biologic therapy treatment) or experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, prior to C1D1. The interval may be reduced to 2 weeks for bone and visceral metastasis therapy. Any major surgical procedure within 6 weeks prior to C1D1.
- History of severe hypersensitivity reactions to other monoclonal antibodies or either the drug substances or inactive ingredients of BHV-1510.
- Has current or previously treated leptomeningeal carcinomatosis.
- Use of OAP1B1 and OATP1B3 inhibitors within 14 days prior to starting trial.
BHV-1510 in Combination Specific Exclusion Criteria:
- Hypersensitivity to cemiplimab or any of its excipients or contraindicated to cemiplimab per approved local labeling.
- Experienced Grade 3 or higher immune-related AEs with prior treatment of anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137).
- Prior allogeneic stem cell or solid organ transplantation.
- Patients with history of myocarditis.
- Presence of cardiovascular disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Augmentation de la dose de BHV-1510 en monothérapie
|
BHV-1510 will be administered on Day 1 every 3 weeks
Autres noms:
BHV-1510 will be administered on Day 1 every 2 weeks
Autres noms:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Autres noms:
|
|
Expérimental: BHV-1510 en association avec une augmentation de dose de Cemiplimab
|
BHV-1510 will be administered on Day 1 every 3 weeks
Autres noms:
BHV-1510 will be administered on Day 1 every 2 weeks
Autres noms:
BHV-1510 will be administered on Day 1 and Day 8 every 3 weeks
Autres noms:
cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks cemiplimab (350mg) will be administered as an IV infusion on Day 1 and Day 8 every 3 weeks |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1: Number of patients with adverse events (AEs)
Délai: Through study completion, estimated as an average of 47 months
|
Description: Incidence and severity of AEs, serious adverse events (SAEs) and dose limiting toxicities (DLTs). Severity of AEs will be assessed according to the NCI CTCAE v5.0. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Recommended doses or schedules for expansion (RDEs) and maximum tolerated dose (MTD)
Délai: Approximately 15 months
|
Based on tolerability and preliminary antitumor activity. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Approximately 15 months
|
|
Phase 2: Objective Response Rate (ORR) for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Number of patients with AEs for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
Incidence and severity of AEs, SAEs and DLTs. Severity of AEs will be assessed according to the NCI CTCAE v5.0 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Duration of Response (DoR) for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Phase 1 et 2: concentration plasmatique maximale (CMAX) du BHV-1510, anticorps total et charge utile (BHC-0080269)
Délai: Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2: zone sous la courbe de concentration par rapport à la fin de la fin de la perfusion à la dernière concentration mesurable (Auclast) de BHV-1510, anticorps total et charge utile
Délai: Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2: zone sous la courbe de concentration par rapport à l'intervalle de dosage (AUCTAU) du BHV-1510, anticorps total et charge utile
Délai: Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2: Half-Life (T1 / 2) de l'élimination du BHV-1510, anticorps total et charge utile
Délai: Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2: Concentration de creux (CTROUGH) du BHV-1510, anticorps total et charge utile
Délai: Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points de temps, mais ne dépassant pas, 22 jours dans les cycles 1 et 3
|
|
|
Phase 2: Effets de la monothérapie et de la charge utile BHV-1510 sur l'intervalle QTC en utilisant la méthode de correction de Fridericia (QTCF), et sur d'autres paramètres ECG (fréquence cardiaque [HR], PR et intervalle QRS)
Délai: Environ 15 mois
|
Environ 15 mois
|
|
|
Phase 1 et 2 : Aire sous la courbe de concentration en fonction du temps extrapolée à l'infini (AUCinf) du BHV-1510, anticorps total et charge utile
Délai: Jusqu'à 8 points temporels, mais sans dépasser 22 jours au Cycle 1
|
Jusqu'à 8 points temporels, mais sans dépasser 22 jours au Cycle 1
|
|
|
Phase 1 et 2 : Clairance corporelle totale (CL) après administration IV ou clairance corporelle totale apparente (CL/F) après administration SC du BHV-1510 et anticorps total
Délai: Jusqu'à 8 points temporels, mais ne dépassant pas 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points temporels, mais ne dépassant pas 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2 : Biodisponibilité relative (%F) après administration sous-cutanée de BHV-1510 et anticorps total
Délai: Jusqu'à 8 points temporels, sans dépasser 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points temporels, sans dépasser 22 jours dans les cycles 1 et 3
|
|
|
Phase 1 et 2 : Volume de distribution à l'état d'équilibre (Vss) après administration IV ou volume de distribution apparent à l'état d'équilibre (Vss/F) après administration SC du BHV-1510 et de l'anticorps total
Délai: Jusqu'à 8 points temporels, mais ne dépassant pas 22 jours dans les cycles 1 et 3
|
Jusqu'à 8 points temporels, mais ne dépassant pas 22 jours dans les cycles 1 et 3
|
|
|
Phase 1: ORR
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1: Duration of Response (DoR)
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1. This applies to both the BHV-1510 monotherapy arm and BHV-1510 in combination with Cemiplimab arm. |
Through study completion, estimated as an average of 47 months
|
|
Phase 1 and 2: Immunogenicity of BHV-1510
Délai: Through study completion, estimated as an average of 47 months
|
Incidence of ADA at baseline and post-treatment, including ADA titer |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Disease control rate (DCR) for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Progression free survival (PFS) for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
Assessed by RECIST v 1.1 |
Through study completion, estimated as an average of 47 months
|
|
Phase 2: Overall survival (OS) for BHV-1510 for monotherapy and in combination with cemiplimab
Délai: Through study completion, estimated as an average of 47 months
|
OS is defined as the time period from the start of administration to death due to any cause |
Through study completion, estimated as an average of 47 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Chief Medical Officer, Biohaven Pharmaceuticals, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- BHV1510-101 (PBI-410-101)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .